Close Menu

NEW YORK (GenomeWeb) - HelixBind, a Marlborough, Massachusetts-based startup, recently became the first entity to receive funding for a molecular diagnostic testing system through CARB-X, an international group intent on combating antibiotic-resistant superbugs.

The HelixBind test system, called RaPID, uses a number of novel approaches, including peptide nucleic acid-, or PNA-based amplification to detect bloodstream infections, said David Steinmiller, the firm's chief business officer.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.